503 related articles for article (PubMed ID: 31699932)
1. Double
Vasan N; Razavi P; Johnson JL; Shao H; Shah H; Antoine A; Ladewig E; Gorelick A; Lin TY; Toska E; Xu G; Kazmi A; Chang MT; Taylor BS; Dickler MN; Jhaveri K; Chandarlapaty S; Rabadan R; Reznik E; Smith ML; Sebra R; Schimmoller F; Wilson TR; Friedman LS; Cantley LC; Scaltriti M; Baselga J
Science; 2019 Nov; 366(6466):714-723. PubMed ID: 31699932
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition.
Spangle JM; Von T; Pavlick DC; Khotimsky A; Zhao JJ; Roberts TM
Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24427-24433. PubMed ID: 32929011
[No Abstract] [Full Text] [Related]
3. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
Hon WC; Berndt A; Williams RL
Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714
[TBL] [Abstract][Full Text] [Related]
4. Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations.
Schwartzberg LS; Vidal GA
Clin Breast Cancer; 2020 Aug; 20(4):e439-e449. PubMed ID: 32278641
[TBL] [Abstract][Full Text] [Related]
5. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
6. Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.
Varkaris A; Fece de la Cruz F; Martin EE; Norden BL; Chevalier N; Kehlmann AM; Leshchiner I; Barnes H; Ehnstrom S; Stavridi AM; Yuan X; Kim JS; Ellis H; Papatheodoridi A; Gunaydin H; Danysh BP; Parida L; Sanidas I; Ji Y; Lau K; Wulf GM; Bardia A; Spring LM; Isakoff SJ; Lennerz JK; Del Vecchio K; Pierce L; Pazolli E; Getz G; Corcoran RB; Juric D
Cancer Discov; 2024 Feb; 14(2):227-239. PubMed ID: 37916958
[TBL] [Abstract][Full Text] [Related]
7. Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines.
Kostopoulou ON; Holzhauser S; Lange BKA; Ohmayer A; Andonova T; Bersani C; Wickström M; Dalianis T
Int J Oncol; 2019 Dec; 55(6):1372-1384. PubMed ID: 31638167
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA in cancer: The past 30 years.
Arafeh R; Samuels Y
Semin Cancer Biol; 2019 Dec; 59():36-49. PubMed ID: 30742905
[TBL] [Abstract][Full Text] [Related]
9. In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
Kong D; Yamori T; Yamazaki K; Dan S
Invest New Drugs; 2014 Dec; 32(6):1134-43. PubMed ID: 25152245
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.
Fritsch C; Huang A; Chatenay-Rivauday C; Schnell C; Reddy A; Liu M; Kauffmann A; Guthy D; Erdmann D; De Pover A; Furet P; Gao H; Ferretti S; Wang Y; Trappe J; Brachmann SM; Maira SM; Wilson C; Boehm M; Garcia-Echeverria C; Chene P; Wiesmann M; Cozens R; Lehar J; Schlegel R; Caravatti G; Hofmann F; Sellers WR
Mol Cancer Ther; 2014 May; 13(5):1117-29. PubMed ID: 24608574
[TBL] [Abstract][Full Text] [Related]
11. CD44/HA signaling mediates acquired resistance to a PI3Kα inhibitor.
Yang C; Sheng Y; Shi X; Liu Y; He Y; Du Y; Zhang G; Gao F
Cell Death Dis; 2020 Oct; 11(10):831. PubMed ID: 33024087
[TBL] [Abstract][Full Text] [Related]
12. Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.
Hanan EJ; Braun MG; Heald RA; MacLeod C; Chan C; Clausen S; Edgar KA; Eigenbrot C; Elliott R; Endres N; Friedman LS; Gogol E; Gu XH; Thibodeau RH; Jackson PS; Kiefer JR; Knight JD; Nannini M; Narukulla R; Pace A; Pang J; Purkey HE; Salphati L; Sampath D; Schmidt S; Sideris S; Song K; Sujatha-Bhaskar S; Ultsch M; Wallweber H; Xin J; Yeap S; Young A; Zhong Y; Staben ST
J Med Chem; 2022 Dec; 65(24):16589-16621. PubMed ID: 36455032
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic PIK3CA mutations increase dependency on the mRNA cap methyltransferase, RNMT, in breast cancer cells.
Dunn S; Lombardi O; Lukoszek R; Cowling VH
Open Biol; 2019 Apr; 9(4):190052. PubMed ID: 30991934
[TBL] [Abstract][Full Text] [Related]
14. A novel carcinogenic PI3Kα mutation suggesting the role of helical domain in transmitting nSH2 regulatory signals to kinase domain.
Ghalamkari S; Alavi S; Mianesaz H; Khosravian F; Bahreini A; Salehi M
Life Sci; 2021 Mar; 269():118759. PubMed ID: 33189828
[TBL] [Abstract][Full Text] [Related]
15. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
[TBL] [Abstract][Full Text] [Related]
16. Genomic Alterations in
Cai Y; Xu G; Wu F; Michelini F; Chan C; Qu X; Selenica P; Ladewig E; Castel P; Cheng Y; Zhao A; Jhaveri K; Toska E; Jimenez M; Jacquet A; Tran-Dien A; Andre F; Chandarlapaty S; Reis-Filho JS; Razavi P; Scaltriti M
Cancer Res; 2021 May; 81(9):2470-2480. PubMed ID: 33685991
[TBL] [Abstract][Full Text] [Related]
17. Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.
Toppmeyer DL; Press MF
Cancer Med; 2020 Sep; 9(18):6463-6472. PubMed ID: 32697890
[TBL] [Abstract][Full Text] [Related]
18. The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer.
VanLandingham NK; Nazarenko A; Grandis JR; Johnson DE
Adv Biol Regul; 2023 Jan; 87():100934. PubMed ID: 36402737
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated mutations in the p85α N-terminal SH2 domain activate a spectrum of receptor tyrosine kinases.
Li X; Lau AYT; Ng ASN; Aldehaiman A; Zhou Y; Ng PKS; Arold ST; Cheung LWT
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34507989
[TBL] [Abstract][Full Text] [Related]
20. Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP.
Menteş M; Karakuzulu BB; Uçar GB; Yandım C
Comput Biol Chem; 2022 Aug; 99():107726. PubMed ID: 35842959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]